Open Access

Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing

  • Authors:
    • Kailian Zheng
    • Tao Liu
    • Jiangman Zhao
    • Peng Meng
    • Yun Bian
    • Chenming Ni
    • Huan Wang
    • Yaqi Pan
    • Shouxin Wu
    • Hui Jiang
    • Gang Jin
  • View Affiliations

  • Published online on: February 25, 2021     https://doi.org/10.3892/etm.2021.9859
  • Article Number: 415
  • Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic neuroendocrine tumor (PNET), a heterogenous type of neoplasm with limited treatment options, is relatively rare and to date, the genetic background has remained to be fully elucidated. The present study aimed to determine the mutational landscape of PNET with and without liver metastasis, as well as its clinical application value for treatment. Fresh tumor tissues were collected from 14 patients with PNET following surgery, 4 of whom had developed liver metastasis. Subsequently, targeted next‑generation sequencing of 612 cancer‑associated genes and comprehensive analysis were performed on the tumor tissues. The results identified 63 somatic mutations in 53 genes in the 14 patients with PNET, amongst which menin 1 was identified as the most recurrently mutated gene. The analysis also identified several novel recurrently mutated genes, including adrenoceptor alpha 2B, ARVCF delta catenin family member, carbamoyl‑phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase and neuregulin 1. Among the 53 mutated genes, 11 were enriched in the PI3K/AKT signaling pathway (adjusted P=7.12x10‑5). In addition, 4 patients with PNET with liver metastasis had distinctly different mutational profiles compared with those without liver metastasis; 13 genes were discovered to be exclusively mutated in the liver metastasis group of the patients with PNET, including ATRX chromatin remodeler, thioredoxin reductase 2, anus kinase 3, ARVCF delta catenin family member, integrin subunit alpha V and RAD50 double strand break repair protein. In addition, two potentially actionable alterations in BRCA2 DNA repair‑associated (p.Q548Q) and neurofibromin 1 (p.Q1188X) were identified using the OncoKB database. In conclusion, the present study generated a comprehensive mutational profile of 14 patients with PNET and further described the features of patients with liver metastasis, which highlights potential targets for drug development of PNET.
View Figures
View References

Related Articles

Copy and paste a formatted citation
x
Spandidos Publications style
Zheng K, Liu T, Zhao J, Meng P, Bian Y, Ni C, Wang H, Pan Y, Wu S, Jiang H, Jiang H, et al: Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing. Exp Ther Med 21: 415, 2021
APA
Zheng, K., Liu, T., Zhao, J., Meng, P., Bian, Y., Ni, C. ... Jin, G. (2021). Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing. Experimental and Therapeutic Medicine, 21, 415. https://doi.org/10.3892/etm.2021.9859
MLA
Zheng, K., Liu, T., Zhao, J., Meng, P., Bian, Y., Ni, C., Wang, H., Pan, Y., Wu, S., Jiang, H., Jin, G."Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing". Experimental and Therapeutic Medicine 21.5 (2021): 415.
Chicago
Zheng, K., Liu, T., Zhao, J., Meng, P., Bian, Y., Ni, C., Wang, H., Pan, Y., Wu, S., Jiang, H., Jin, G."Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next‑generation sequencing". Experimental and Therapeutic Medicine 21, no. 5 (2021): 415. https://doi.org/10.3892/etm.2021.9859